GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TransCode Therapeutics Inc (NAS:RNAZ) » Definitions » Cash per Share

RNAZ (TransCode Therapeutics) Cash per Share : $5.65 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is TransCode Therapeutics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). TransCode Therapeutics's Cash per Share for the quarter that ended in Dec. 2024 was $5.65.

TransCode Therapeutics Cash per Share Historical Data

The historical data trend for TransCode Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransCode Therapeutics Cash per Share Chart

TransCode Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash per Share
Get a 7-Day Free Trial - - - 145.68 5.65

TransCode Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 145.68 27.92 15.25 3.59 5.65

TransCode Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

TransCode Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=5.811/1.03
=5.65

TransCode Therapeutics's Cash per Share for the quarter that ended in Dec. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=5.811/1.03
=5.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransCode Therapeutics  (NAS:RNAZ) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

TransCode Therapeutics Cash per Share Related Terms

Thank you for viewing the detailed overview of TransCode Therapeutics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

TransCode Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TransCode Therapeutics Inc (NAS:RNAZ) » Definitions » Cash per Share
Comparable Companies
KRBPQ RMTG CYTOF AIBT GSTC CNBX HEPA GBLX ENDV PPCB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
6 Liberty Square, Suite 2382, Boston, MA, USA, 02109
Website
https://www.transcodetherapeutics.com
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
Executives
Robert Michael Dudley director, 10 percent owner, officer: Chief Executive Officer C/O TRANSCODE THERAPEUTICS, 6 LIBERTY SQUARE #2382, BOSTON MA 02109
Thomas A Fitzgerald director, officer: VP, Chief Financial Officer C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Philippe Calais director C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Anna Moore 10 percent owner C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE #2382, BOSTON MA 02109
Zdravka Medarova 10 percent owner C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109
Erik Manting director C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109